The creation of retatrutide, a novel dual activator targeting both GLP-1 and GIP receptors, involves a complex complicated synthetic process. Early routes focused on amino acid chain section coupling, utilizing solid-phase synthesis methodologies to build the long protein sequence. Subsequent research has explored various approaches, including enzy